US-China biotech NeuShen gets $80M to develop brain-health drugs

A Shanghai and Boston biotech led by a veteran transpacific drug developer has secured more than $80 million to advance three clinical-stage brain-health drugs. NeuShen Therapeutics disclosed the Series B this ...